Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | terminated | Phase 1 | 2 | Celgene CorporationINDUSTRY | 1 | Jul 28, 2015 | clinicaltrials |
| NCT00363779 | Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2015 | clinicaltrials |
| NCT01497275 |
| Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma |
| terminated |
| Phase 2 |
| 5 |
| Duke UniversityOTHER |
| 1 |
| Jul 15, 2015 |
| clinicaltrials |
| NCT00905398 | Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(ALLPhi) | terminated | Phase 1 / Phase 2 | 8 | Rony SchaffelOTHER | 0 | Jul 9, 2015 | clinicaltrials |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | terminated | Phase 2 | 4 | Valerio TherapeuticsINDUSTRY | 1 | Jul 8, 2015 | clinicaltrials |
| NCT00358982 | Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma | terminated | Phase 2 | 51 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 3, 2015 | clinicaltrials |
| NCT00543582 | MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma | terminated | Phase 2 | 23 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00522392 | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone | terminated | Phase 3 | 48 | National Cancer Institute (NCI)NIH | 2 | Jun 26, 2015 | clinicaltrials |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | terminated | Phase 1 | 11 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | terminated | Phase 1 / Phase 2 | 28 | University of MichiganOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone | terminated | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 1, 2015 | clinicaltrials |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 6 | University of ArkansasOTHER | 1 | Apr 6, 2015 | clinicaltrials |
| NCT00210392 | VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy | terminated | Phase 2 | 12 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Mar 30, 2015 | clinicaltrials |
| NCT01100658 | Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors | terminated | N/A | 1 | University of MinnesotaOTHER | 1 | Mar 27, 2015 | clinicaltrials |
| NCT00077961 | Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL | terminated | Phase 1 / Phase 2 | 49 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 26, 2015 | clinicaltrials |
| NCT00748631 | Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.(KYPHOK) | terminated | N/A | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 24, 2015 | clinicaltrials |
| NCT00185679 | Haploid Allogeneic Transplant Using the CliniMACS System | terminated | Phase 2 | 13 | Ginna LaportOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT02353468 | Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | terminated | Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00005834 | S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma | terminated | Phase 3 | 19 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00051701 | Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 61 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00529503 | A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL | terminated | Phase 2 | 151 | Seagen Inc.INDUSTRY | 10 | Feb 25, 2015 | clinicaltrials |
| NCT00891033 | Panobinostat/Velcade in Multiple Myeloma | terminated | Phase 1 | 12 | University of ArkansasOTHER | 1 | Feb 23, 2015 | clinicaltrials |
| NCT01449539 | Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization | terminated | N/A | 8 | University of ArkansasOTHER | 1 | Feb 23, 2015 | clinicaltrials |
| NCT01302366 | A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma | terminated | Phase 2 | 20 | NYU Langone HealthOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT00916045 | Pilot Study of Unrelated Cord Blood Transplantation | terminated | Phase 2 | 40 | King's College Hospital NHS TrustOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT02070393 | Breast-Sparing Proton Therapy for Hodgkin's Disease(Breast Sparing) | terminated | Early Phase 1 | 3 | Indiana UniversityOTHER | 1 | Feb 4, 2015 | clinicaltrials |
| NCT01537861 | Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma | terminated | Early Phase 1 | 7 | Washington University School of MedicineOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00060671 | Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma | terminated | Phase 3 | 800 | CTI BioPharmaINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
| NCT00719901 | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT01078441 | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT00649584 | A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies | terminated | Phase 1 | 44 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT01653418 | Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation(V-BEAM) | terminated | Phase 2 | 10 | Washington University School of MedicineOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | terminated | N/A | 10 | Indiana UniversityOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | BiogenINDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT00240162 | PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma | terminated | Phase 2 | 21 | Washington University School of MedicineOTHER | 1 | Sep 17, 2014 | clinicaltrials |
| NCT00225173 | Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease | terminated | Phase 2 | 45 | Stanford UniversityOTHER | 1 | Aug 27, 2014 | clinicaltrials |
| NCT01914718 | Dose-adjusted EPOCH-R in MYC Positive DLBCL | terminated | Phase 2 | 26 | Fudan UniversityOTHER | 1 | Aug 20, 2014 | clinicaltrials |
| NCT01301963 | Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide | terminated | Phase 3 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2014 | clinicaltrials |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma | terminated | Phase 2 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 30, 2014 | clinicaltrials |
| NCT01534949 | Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial(Triad-DLBCL) | terminated | Phase 1 | 1 | CelltrionINDUSTRY | 1 | Jul 23, 2014 | clinicaltrials |
| NCT01078922 | Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas | terminated | Phase 2 | 11 | Oncology Specialists, S.C.OTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT01466868 | Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma(AKTIL) | terminated | Phase 2 | 22 | Centre Leon BerardOTHER | 1 | Jul 10, 2014 | clinicaltrials |
| NCT02079519 | A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma | terminated | Phase 2 | 10 | Hoffmann-La RocheINDUSTRY | 1 | Jul 8, 2014 | clinicaltrials |
| NCT00365274 | SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jul 28, 2015source: clinicaltrials